CST, 26981T, Podoplanin (LpMab-12) Mouse Monoclonal Antibody

Monoclonal Antibody for studying Podoplanin. Validated for Immunohistochemistry (Paraffin),Flow Cytometry (Fixed/Permeabilized),Flow Cytometry (Live). Available in 2 sizes. Highly specific and rigorously validated in-house, Podoplanin (LpMab-12) Mouse Monoclonal Antibody (CST #26981) is ready to ship. Product Usage Information Immunohistochemistry (Paraffin): 1:125 - 1:500 Flow Cytometry (Fixed/Permeabilized): 1:400 - 1:1600 Flow Cytometry (Live): 1:400 - 1:1600 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Immunohistochemistry (Paraffin), Flow Cytometry (Fixed/Permeabilized), Flow Cytometry (Live) Specificity / Sensitivity Podoplanin (LpMab-12) Mouse Monoclonal Antibody recognizes endogenous levels of human podoplanin. The antibody specifically recognizes podoplanin that is sialylated on Thr52 in the third platelet aggregation domain (PLAG3) of human podoplanin (10). Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with LN-229 glioma cells expressing human podoplanin. Background Podoplanin (aggrus, glycoprotein 36) is a single-pass transmembrane protein belonging to the type-1 family of sialomucin-like glycoproteins. Podoplanin was first described in the rat as a surface glycoprotein that regulated podocyte morphology (1). It is now commonly used as a marker of lymphatic endothelial cells, where its expression is associated with the process of lymphangiogenesis (2). Its role in this regard is presumably due to its putative involvement in regulating actin cytoskeleton dynamics (3). Research studies have shown that podoplanin expression is upregulated in a number of tumor types including colorectal cancers (4), oral squamous cell carcinomas (5), and germ cell tumors (6), with higher expression levels often associated with more aggressive tumors (7). Research studies have suggested a functional role for podoplanin in the stromal microenvironment of tumors. For example, it has been reported that podoplanin expression in cancer-associated fibroblasts (CAFs) is positively associated with a stromal environment that promotes cancer progression (8,9). Podoplanin is O-glycosylated at multiple sites in the extracellular domain, including disialylation at Thr52 in the third platelet-aggregation (PLAG3) domain (10). Research studies have shown that glycoylation at this site is required for tumor cell-induced platelet aggregation activity (11). Alternate Names 29kDa cytosolic podoplanin intracellular domain; Aggrus; Glycoprotein 36; glycoprotein, 36-KD; GP36; Gp38; GP40; HT1A-1; hT1alpha-1; hT1alpha-2; lung type I cell membrane associated glycoprotein; lung type-I cell membrane-associated glycoprotein; lung type-I cell membrane-associated glycoprotein (T1A-2); OTS8; PA2.26; PA2.26 antigen; PDPN; PICD; Podoplanin; T1-alpha; T1A; T1A-2; T1A2; TI1A Specification REACTIVITY: H SENSITIVITY: Endogenous Source/Isotype: Mouse IgG1